Clinical Trial Update: HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating HA-1 TCR T-cell immunotherapy for relapsed or refractory acute leukemia after donor stem cell tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Mixed Phenotype Acute Leukemia
• Undifferentiated Leukemia

Drugs mentioned

• HA-1 TCR T-cell immunotherapy (HA-1 T cell receptor (TCR) T-cell therapy)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Status: RECRUITING